Abstract: A process enables efficient preparation of liposome-encapsulated peptide P33. The process comprising preparing a peptide P33; preparing a lipid mixture by dissolving 70-90 mg of phospholipid including granulated soy lecithin and 20 mg of cholesterol in 15-25 mg of a chloroform/methanol solvent system; evaporating organic solvent using a magnetic stirrer coupled with a heating system until a lipid film is fully formed and hydrated; removing solvent traces by drying the lipid film under vacuum conditions overnight; rehydrating the lipid film with 8-12 mL of a buffer containing 190-210 ?g/mL of peptide P33; mixing the rehydrated lipid film thoroughly using a magnetic stirrer at ambient temperature to ensure uniform dispersion; sonicating the lipid suspension until a clear, translucent solution is obtained; and extruding the resulting suspension using a vortex to form large unilamellar vesicles (LUVs) with a uniform size of approximately 200 nm.

Abstract: The present invention provides a formulation of Ginsenoside Rg3-loaded niosomes enhance its pharmacokinetic properties and improve its anticancer efficacy, both in vitro and in silico, by facilitating targeted delivery and interaction with key cancer-related molecules such as Cathepsin B. The present invention provides a method for synthesizing Ginsenoside Rg3-loaded nanoniosomes, comprising dissolving cholesterol and Span 80 in chloroform to form a lipid phase; dissolving Ginsenoside Rg3 in methanol and transferring the dissolved Ginsenoside Rg3 into the lipid phase; evaporating the chloroform and methanol solvent mixture at a temperature of 40° C. to form a thin lipid film; hydrating the thin lipid film using phosphate-buffered saline (PBS) for 25 minutes at 45° C. to form the nanoniosomal formulation; cooling the formulation overnight; and subjecting the formulation to sonication for 40 minutes to reduce the mean vesicle size.

Abstract: The present invention generally relates to a process for manufacturing gel composition of Luliconazole for treatment of vaginal fungal infections cooling 50% quantity of purified water at 4° C.; adding 0.10-0.30% of Carbopol 934, 5-15% of poloxamer 188 and 15-25% of poloxamer 407 slowly under constant stirring and placing at 4° C., until a clear solution is obtained; adding 0.1-0.5% HPMC K100M gradually under stirring and leaving for 24 hours at room temperature; adding 0.5-2% Luliconazole solution slowly under high speed homogenizer; adding 0-0.5% Sodium methyl parabens and 0-1% Sodium propyl parabens solution under constant stirring; adding 0.1-0.5% sodium chloride under stirring; checking and maintaining pH of the obtained solution; and preparing the obtained solution volume to 100% with purified water and stirring for 30 min for manufacturing gel composition of Luliconazole.

Abstract: The present invention generally relates to a process for preparing polymeric-based nanoparticle of RPD coated with Tf and RVG comprises dissolving 1-12 wt % of RPD and 8-96 wt % of lipid in isopropyl alcohol (IPA) and heating the solution to 70° C. to create the organic phase; adding prepared organic solution to the 0-2 wt % of aqueous surfactant solution using a syringe at 70° C. temperature; swirling the obtained solution at 1000 rpm on a high speed homogenizer for 15 minutes after the solvent is evaporated using a magnetic stirrer to create the SLNs dispersion; and adding 45-100 wt % of Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 45-100 wt % of N-Hydroxysulfosuccinimide (NHS), which included activating the carboxylic acid terminal groups and conjugating Tf and RVG to RPD's PLGA nanoparticles.

Abstract: Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

Abstract: Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

Abstract: Self-nanoemulsifying drug delivery system (SNEDDS) composition are provided. The compositions include at least one chemotherapeutic compound or a pharmaceutically acceptable salt thereof or mixture thereof, at least one biocompatible surfactant, wherein the at least one biocompatible surfactant includes surfactin, and at least one co-surfactant. Methods of enhancing the bioavailability of the chemotherapeutic compound and for treating cancer are also provided.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.